AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20961967
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg/day, n=33)
Trial: 31563388
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS treatment
Trial: 20633407
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS treatment
Trial: 17701857
Drug: Sonographic examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sonographic examination after 3 months of abstinence therapy
Trial: 14675243
Drug: PFL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFL therapy (13 mg/m2 CDDP, 300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Trial: 14675243
Drug: FL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL therapy (300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Trial: 14675243
Drug: FL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL therapy
Trial: 14675243
Drug: PFL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFL therapy
Trial: 14675243
Drug: PFL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFL therapy and FL therapy
Trial: 11399714
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (RBC transfusions at hemoglobin concentration of 7.0 g/dL, maintained between 7.0 g/dL and 9.0 g/dL)
Trial: 11399714
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (RBC transfusions at hemoglobin concentration of 10.0 g/dL, maintained between 10.0 g/dL and 12.0 g/dL)
Trial: 9579845
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intraperitoneal chemotherapy with FU/LV (LV 200 mg m(‐2) plus FU 350 mg m(‐2), administered intravenously on days 1-4 and intraperitoneally on days 1 and 3 every 4 weeks for a total of six courses)
Trial: 9579845
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with FU and levamisole (given for a duration of 6 months)
Trial: 7660219
Drug: Methimazole 30
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole 30 mg once daily
Trial: 7660219
Drug: Propylthiouracil 100
RxNorm normalized name: propylthiouracil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylthiouracil 100 mg every 8 hours
Trial: 25988924
Drug: Review of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Review of clinical features, treatment, and prognosis
Trial: 19278581
Drug: Thymosin alpha1
RxNorm normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha1 (1.6 mg subcutaneous injection per day for 7 days)
Trial: 19278581
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CBP + thymosin alpha1)
Trial: 9555126
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (sulfasalazine, prednisolone, and methotrexate)
Trial: 7894897
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of herpetic keratitis
Trial: 2974630
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin (SCT) 100 IU, administered four times a week for 8 weeks
Trial: 2974630
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml saline), administered four times a week for 8 weeks
Trial: 31881621
Drug: Hydrocodone/Acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/Acetaminophen
Trial: 29584496
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Alprazolam and Hydrocodone/Acetaminophen
Trial: 21487150
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C daily during training
Trial: 19735378
Drug: Immediate HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate HRT (tibolone 2.5 mg)
Trial: 19735378
Drug: Delayed HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed HRT (tibolone 2.5 mg)
Trial: 17023156
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of dacarbazine monotherapy followed by the same 4-drug regimen of chemoimmunotherapy (arm B)
Trial: 11004846
Drug: bFGF in
RxNorm normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF in BAL from s.A (1.79 pg/ml) and s.B (1.48 pg/ml) in sarcoidosis patients
Trial: 11004846
Drug: VEGF in
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF in BAL from s.A (107.5 pg/ml) and s.B (109.7 pg/ml) in sarcoidosis patients
Trial: 9133694
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 131I treatment and early thyroxine
Trial: 4024920
Drug: Balanced glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced glucose infusion
Trial: 29903785
Drug: Internet-mediated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-mediated cognitive behavioural therapy (ICBT)
Trial: 11572225
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy
Trial: 23872720
Drug: Intravenous sivelestat,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sivelestat, n = 8
Trial: 23872720
Drug: Intravenous saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline, n = 8
Trial: 23043036
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin
Trial: 14743227
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin
Trial: 12398965
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg twice daily)
Trial: 1915427
Drug: Pimobendan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (5 mg twice daily)
Trial: 31433355
Drug: E2 vaginal
RxNorm normalized name: Prostin E2 Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 vaginal inserts (4, 10, or 25?g)
Trial: 27237772
Drug: Uphill treadmill
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uphill treadmill training for 30 minutes daily for 6 weeks
Trial: 25866811
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid liposome (UAL) at 56 mg/m2
Trial: 25866811
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid liposome (UAL) at 74 mg/m2
Trial: 25866811
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid liposome (UAL) at 98 mg/m2
Trial: 25866811
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid liposome (UAL) at 74 mg/m2 for pharmacokinetics
Trial: 18318569
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg once daily for 5 days
Trial: 19419343
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once daily on day 1 and 250 mg once daily on days 2 through 5
Trial: 14759955
Drug: Web intervention
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Web intervention group with continuous access to a bioterrorism educational Web site and weekly exposure to case scenarios.
Trial: 30390870
Drug: Milk-honey mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-honey mixture (twice a day for three days)
Trial: 27166794
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of folic acid daily (Group 1)
Trial: 27166794
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of folic acid daily (Group 2)
Trial: 25594129
Drug: Combination blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination blue light therapy (n = 26)
Trial: 23870722
Drug: 1.2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/day n-3 PUFAs
Trial: 21691804
Drug: TNF‐α blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α blockers (Infliximab and Adalimumab)
Trial: 21691804
Drug: TNF‐α blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α blockers
Trial: 21691804
Drug: Control (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Placebo or other drugs)
Trial: 18378871
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of angina and major depression, not using diuretics
Trial: 16113850
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic drugs (dipirone or diazepan)
Trial: 16113850
Drug: Anti-hypertensive drug
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive drug (captopril)
Trial: 12944062
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (historical controls)
Trial: 8815681
Drug: Polyclonal immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal immunoglobulin administration
Trial: 8815681
Drug: Monoclonal anti‐CMV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal anti‐CMV antibodies (MSL‐109)
Trial: 1612492
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (5 mg four times daily)
Trial: 6430142
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium citrate (1.3 meq/kg body weight daily for 8 weeks)
Trial: 6430142
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (for 8 weeks)
Trial: 6430142
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium citrate
Trial: 6430142
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium citrate and acetate dialysate
Trial: 28744993
Drug: Machined implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined implants in smokers
Trial: 26065445
Drug: Metronidazole 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1,000 mg (single oral dose)
Trial: 20037644
Drug: FP9-TRAP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP9-TRAP vaccine
Trial: 20037644
Drug: MVA-TRAP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-TRAP vaccine
Trial: 20037644
Drug: FFM ME-TRAP
RxNorm normalized name: Trapa bicornis seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFM ME-TRAP vaccine
Trial: 16773437
Drug: Paclitaxel (175,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175, 210, and 250 mg/m² over 3 h every 3 weeks)
Trial: 12842680
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia of proparacaine 0.5% without i.v. cannula
Trial: 11085807
Drug: 10,640 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,640 IU 25-HCC per week + 1 g calcium per day
Trial: 2876183
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g calcium per day
Trial: 1615177
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone diproprionate (1500 micrograms day‐1)
Trial: 6377865
Drug: Propranolol b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol b.i.d. (80, 160, 320 mg/day)
Trial: 6377865
Drug: Propranolol q.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol q.i.d. (80, 160, 320 mg/day)
Trial: 6377865
Drug: Propranolol q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol q.d. (80, 160, 320 mg/day)
Trial: 30360658
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (250 μg daily)
Trial: 30027756
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions over 10 weeks)
Trial: 23182608
Drug: Remifentanil 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.75 μg/kg
Trial: 27687441
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 μg/kg
Trial: 23182608
Drug: Remifentanil 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.25 μg/kg
Trial: 24488793
Drug: Standardized postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized postoperative treatment plan alone (no preoperative cryotherapy)
Trial: 20070143
Drug: Famciclovir 1000
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Famciclovir 1000 mg twice-daily
Trial: 31377160
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy (RT) alone
Trial: 12110494
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (1000 mg/m2) on day 1 preceding cisplatin infusion, 30 mg/m2/24 h cisplatin intravenous bolus days 1-4, and 1000 mg/m2/24 h 5-FU in a 4-h infusion on days 1-4.
Trial: 12110494
Drug: Cisplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (30 mg/m2/24 h) and 5-FU in the same dosage and schedule as in arm A.
Trial: 8524975
Drug: m‐chlorophenylpiperazine (m‐CPP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐chlorophenylpiperazine (m‐CPP, 0.08 mg/kg IV) with scopolamine (0.4 mg IV)
Trial: 8524975
Drug: scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (0.4 mg IV)
Trial: 8524975
Drug: ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.15 mg/kg IV)
Trial: 8524975
Drug: scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (0.4 mg IV) + ondansetron (0.15 mg/kg IV)
Trial: 27018419
Drug: Triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.5 mg
Trial: 6128231
Drug: Flunitrazepam 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.5 mg
Trial: 6101959
Drug: Flunitrazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.25 mg
Trial: 21539759
Drug: Nalbuphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (10 mg/1 ml)
Trial: 12382386
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 ml)
Trial: 19438689
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ablative fractional laser resurfacing and nonablative laser resurfacing
Trial: 17084249
Drug: Torcetrapib 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 10, 30, 60, or 90 mg/day
Trial: 19029469
Drug: Torcetrapib plus
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib plus atorvastatin
Trial: 7569283
Drug: Mesoglycan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan 100 mg
Trial: 7569283
Drug: Mesoglycan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan 50 mg
Trial: 7002481
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection with placebo
Trial: 7002481
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection with active tolmetin sodium
Trial: 24284101
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (ALA), 1.0 g, orally administered
Trial: 18714218
Drug: Caffeine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing supplement (SUPP) - 201 mg of caffeine
Trial: 16353199
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1500 mg 3 times daily) plus vitamin D(3) 400 IU
Trial: 14723480
Drug: Concurrent smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent smoking cessation treatment offered during intensive rehabilitation for alcohol dependence.
Trial: 14723480
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment offered six months following intensive rehabilitation for alcohol dependence.
Trial: 15964160
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg
Trial: 15106359
Drug: Tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 1.25 mg
Trial: 11991445
Drug: E2/NETA (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (estradiol 2 mg plus norethindrone acetate 1 mg)
Trial: 9806503
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (ChT) followed by standard radiation therapy (RT) (60 Gy in 6 weeks)
Trial: 9806503
Drug: Combined sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sequential and concurrent ChT and standard RT (60 Gy in 6 weeks)
Trial: 9806503
Drug: Sequential ChT
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ChT followed by standard RT (60 Gy in 6 weeks)
Trial: 28435128
Drug: Fast-track protocol
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track protocol (no preoperative bowel preparation, early restoration of diet, no postoperative antibiotics, early postoperative mobilization)
Trial: 24354899
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin pump training
Trial: 20199764
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV-7)
Trial: 17112807
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg/d for 8 days)
Trial: 15098972
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide 0.01% in combination with tretinoin and hydroquinone
Trial: 15098972
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone as monotherapy
Trial: 20525031
Drug: Behavioral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatments for co-occurring SUD and PTSD (specifics not provided)
Trial: 15972378
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (platinum-based regimens)
Trial: 15972378
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (specific regimens not detailed)
Trial: 12004845
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adjuvant chemotherapy)
Trial: 10505538
Drug: Medium-dose hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose hirudin
Trial: 10505538
Drug: Low-dose hirudin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hirudin